A Double-Blind, Placebo- and Positive-Controlled, Randomized, Partial 6-way Crossover Study to Investigate the Pharmacodynamics and Pharmacokinetics of CEP-26401 (5, 25, and 125 microg) Following Single-Dose Administration to Healthy Subjects

Trial Profile

A Double-Blind, Placebo- and Positive-Controlled, Randomized, Partial 6-way Crossover Study to Investigate the Pharmacodynamics and Pharmacokinetics of CEP-26401 (5, 25, and 125 microg) Following Single-Dose Administration to Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2014

At a glance

  • Drugs Irdabisant (Primary) ; Donepezil; Modafinil
  • Indications Cognition disorders
  • Focus Pharmacodynamics
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 02 Apr 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 18 Oct 2013 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 18 Oct 2013 Planned end date changed from 1 Dec 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top